Livzon Pharmaceutical Group Inc. (01513) published its Monthly Return for the period ended 31 January 2026. According to the announcement, the authorized share capital of H shares and A shares remained at RMB 299,807,117 and RMB 588,100,054 respectively, maintaining a total of RMB 887,907,171.

As of the end of January 2026, the company’s H shares in issue stood at 299,807,117, while A shares totaled 588,100,054. The H share public float requirement was confirmed to be in compliance. No new share options, warrants, convertibles, or other share issuance agreements were disclosed for January.